• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Anne McGeorge, Former Managing Partner of Grant Thornton LLP, Joins CitiusTech’s Board of Directors and Chair of the Audit Committee

    1/12/21 9:07:00 AM ET
    $TLMD
    $MGTA
    Managed Health Care
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TLMD alert in real time by email

    PRINCETON, N.J.--(BUSINESS WIRE)--CitiusTech, a leading provider of healthcare technology services and solutions, announced today that Anne McGeorge, former Managing Partner of Grant Thornton’s Global Health Care and Life Sciences Practices, has joined its Board of Directors and chair of the Audit Committee.

    Ms. McGeorge comes with over 35 years of experience advising healthcare clients in all aspects of finance and transformational change, including strategy, M&A, joint ventures, financial statement audits, corporate restructuring, governance, talent acquisition, executive compensation, IRS matters and risk management. She created the healthcare / life sciences practice for Grant Thornton and grew it to a $250 million global business in a little over 10 years. Prior to spending over 11 years at Grant Thornton, Ms. McGeorge was a Partner at Deloitte and at Arthur Andersen LLP.

    “CitiusTech has a very robust business model that cuts across various facets of the healthcare IT industry, enabling it to utilize technology to resolve business challenges faced by healthcare organizations,” said Ms. McGeorge. “As CitiusTech partners with healthcare organizations to accelerate innovation and the landscape transforms over the next three to five years, I look forward to working with the Board and leadership team to help realize this vision."

    Ms. McGeorge is currently a Board member and the audit committee chair of Magenta Therapeutics (NASDAQ: MGTA) and SOC Telemed (NASDAQ: TLMD). She is also an operating partner for Havencrest Healthcare, a healthcare private equity firm, and an advisory board member for FCA Innovations, a healthcare venture capital firm. She is on the faculty of the UNC Gillings School of Global Public Health and is a past instructor for Duke University's various post-graduate Certificate Programs. A member of the Women Business Leaders in Healthcare, she holds a Bachelor of Business Administration in Accounting from the College of William and Mary and a Master of Science in Accounting/Taxation from the University of Virginia.

    “We are excited to welcome Anne McGeorge to our Board of Directors and as chair of our audit committee,” said Dr. Bill Winkenwerder, Chairman of CitiusTech. “She is a results-driven leader with a passion for the healthcare industry and has a strong track record of leading transformation and innovation. We look forward to working closely with Anne to take CitiusTech to the next level of growth.”

    About CitiusTech

    CitiusTech (www.citiustech.com) is a major provider of healthcare technology services and solutions to medical technology companies, providers, payers and life sciences organizations, with over 4,000 professionals worldwide. CitiusTech’s services and solutions include management consulting, healthcare software development, healthcare interoperability, regulatory compliance, BI/analytics, consumer engagement, care coordination and population health management. CitiusTech helps customers accelerate innovation in healthcare through solutions and accelerators for clinical quality reporting, healthcare big data, cloud computing, mobile health and predictive analytics. With cutting-edge technology expertise, world-class service quality and a global resource base, CitiusTech consistently delivers best-in-class solutions and an unmatched cost advantage to healthcare clients worldwide.

    Get the next $TLMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TLMD
    $MGTA

    CompanyDatePrice TargetRatingAnalyst
    Magenta Therapeutics Inc.
    $MGTA
    8/25/2022$2.00Buy → Neutral
    Goldman
    SOC Telemed Inc.
    $TLMD
    4/1/2022$3.00Neutral
    Credit Suisse
    SOC Telemed Inc.
    $TLMD
    2/7/2022$2.00 → $3.00Neutral
    Credit Suisse
    SOC Telemed Inc.
    $TLMD
    2/4/2022Buy → Hold
    Benchmark
    SOC Telemed Inc.
    $TLMD
    2/3/2022$6.00 → $3.00Outperform → Sector Perform
    RBC Capital
    SOC Telemed Inc.
    $TLMD
    2/3/2022$4.00 → $3.00Outperform → Neutral
    Baird
    Magenta Therapeutics Inc.
    $MGTA
    1/24/2022$13.00 → $6.00Buy
    B. Riley Securities
    SOC Telemed Inc.
    $TLMD
    1/7/2022$6.00 → $2.00Outperform → Neutral
    Credit Suisse
    More analyst ratings

    $TLMD
    $MGTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Magenta Therapeutics downgraded by Goldman with a new price target

      Goldman downgraded Magenta Therapeutics from Buy to Neutral and set a new price target of $2.00

      8/25/22 7:54:07 AM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Credit Suisse resumed coverage on SOC Telemed with a new price target

      Credit Suisse resumed coverage of SOC Telemed with a rating of Neutral and set a new price target of $3.00

      4/1/22 7:17:19 AM ET
      $TLMD
      Managed Health Care
      Health Care
    • Credit Suisse reiterated coverage on SOC Telemed with a new price target

      Credit Suisse reiterated coverage of SOC Telemed with a rating of Neutral and set a new price target of $3.00 from $2.00 previously

      2/7/22 8:24:46 AM ET
      $TLMD
      Managed Health Care
      Health Care

    $TLMD
    $MGTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Carr Edward

      4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

      1/26/24 4:51:02 PM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Veness Adam M

      4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

      1/26/24 4:46:18 PM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Randhawa Simrat

      4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

      1/26/24 4:43:38 PM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLMD
    $MGTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Fairmount Funds Management Llc bought $336,252 worth of shares (24,670 units at $13.63) (SEC Form 4)

      4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

      10/3/23 4:00:40 PM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fairmount Funds Management Llc bought $394,500 worth of shares (30,000 units at $13.15) (SEC Form 4)

      4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

      9/28/23 5:09:20 PM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Randhawa Simrat bought $52,800 worth of shares (4,000 units at $13.20)

      4 - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Issuer)

      9/25/23 4:15:07 PM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLMD
    $MGTA
    Financials

    Live finance-specific insights

    See more
    • Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan

      CAMBRIDGE, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (NASDAQ:MGTA) ("Magenta" or the "Company") today announced that its Board of Directors (the "Board") has unanimously adopted a limited duration stockholder rights plan (the "Rights Plan"). The Rights Plan will give the Board sufficient time to conduct its previously announced comprehensive review of strategic alternatives focused on maximizing shareholder value. The Rights Plan has been adopted in order to protect the best interests of the Company and its shareholders, help ensure that all interested parties have the opportunity to participate fairly in the strategic review process, and provide the Board and sh

      3/31/23 4:10:00 PM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates

      – MGTA-117 preliminary clinical results from 15 patients across three dose-escalation cohorts of the ongoing Phase 1/2 clinical trial shows single-agent activity with no dose-limiting toxicities; transition to patients with transplant-eligible AML/MDS expected in H1 2023 pending regulatory alignment – – CD45 antibody-drug conjugate (CD45-ADC) IND-enabling studies are advancing – – MGTA-145 clinical trial for stem cell mobilization in sickle cell disease patients is progressing with data now expected to be shared H1 2023 – – Conference call and webcast scheduled for 8:30am ET / 7:30am CT on December 13, 2022 – CAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (NAS

      12/12/22 4:30:00 PM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial

      CAMBRIDGE, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it will host a conference call and webcast at 8:30 a.m. Eastern Time (ET) / 7:30 a.m. Central Time (CT) tomorrow, Tuesday, December 13, 2022 to review the MGTA-117 clinical data from its ongoing Phase 1/2 does escalation clinical trial that will be presented at the 2022 American Society of Hematology (ASH) Annual Meeting. The oral presentation at ASH, entitled "MGTA-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants

      12/12/22 8:00:00 AM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLMD
    $MGTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Securonix Appoints Eunice Kim as General Counsel

      Veteran Legal Executive Brings More Than Two Decades of Experience in Private and Public Sector Regulatory Affairs, Ethics and Compliance to Unified Defense SIEM Leader Securonix, Inc., a leader in Unified Defense SIEM, today announced the appointment of Eunice Kim as general counsel. In this role, Kim will be responsible for leading Securonix's legal and compliance functions, enhancing processes for evaluating expansion and growth opportunities, and implementing corporate policies that support the company's mission, vision and values. "Eunice is a dynamic legal executive, and we are thrilled to welcome her to Securonix," said Nayaki Nayyar, Chief Executive Officer, Securonix. "Her prov

      11/30/23 10:00:00 AM ET
      $TLMD
      Managed Health Care
      Health Care
    • Magenta Therapeutics Announces Completion of Merger with Dianthus Therapeutics and Implementation of Reverse Stock Split

      CAMBRIDGE, Mass., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics, Inc. (NASDAQ:MGTA) ("Magenta") today announced completion of the merger with Dianthus Therapeutics, Inc. ("Dianthus") following Magenta's successful receipt of stockholder approval for all proposals related to the merger at a special meeting of stockholders. Magenta effected a reverse stock split of Magenta's common stock immediately prior to the merger. Magenta following the merger is referred to herein as the "combined company." Steve Mahoney, President and Chief Financial and Operating Officer of Magenta said, "We are pleased with the outcome of the special meeting and appreciate our stockholders' support for th

      9/11/23 11:33:45 AM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement

      Merger to create Nasdaq-listed, clinical-stage biotechnology company focused on advancing Dianthus' portfolio of next-generation antibody complement therapeutics Combined company is expected to have approximately $180 million of cash or cash equivalents at close, including approximately $70 million from a concurrent private financing by Dianthus' new and existing investors, which is expected to provide funding into mid-2026 Cash expected to fund lead program DNTH103 through multiple clinical data catalysts including Phase 1 in healthy volunteers, and Phase 2 trials in generalized Myasthenia Gravis and other indications Companies will host a joint webcast today, May 3, 2023 at 8:30 a.m. ET

      5/3/23 7:00:00 AM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLMD
    $MGTA
    Leadership Updates

    Live Leadership Updates

    See more
    • Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors

      CAMBRIDGE, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that it has appointed Michael Vasconcelles, M.D. to its board of directors. Dr. Vasconcelles will also serve on the company's R&D Committee and Nominating and Corporate Governance Committee.  "We are delighted to welcome Mike Vasconcelles to the Magenta board," said Jason Gardner, D.Phil., President and Chief Executive Officer, Magenta Therapeutics. "Dr. Vasconcelles brings deep experience in research, medical operations, clinical trial design

      8/17/22 8:00:00 AM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Magenta Therapeutics Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer

      Magenta Therapeutics, Inc. (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplants to more patients, today announced the appointment of Jeffrey Humphrey, M.D., as the company's Chief Medical Officer where he will be responsible for all clinical development and regulatory initiatives. Dr. Humphrey is a medical oncologist with significant leadership experience in drug development and has been involved with the development of more than 20 drug candidates, including regulatory submissions leading to multiple drug approvals in the United States and Europe. "As Magenta continues to advance our clinical and pr

      10/4/21 8:00:00 AM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Magenta Therapeutics Appoints Caren Deardorf as Chief Commercial Officer

      Magenta Therapeutics, Inc. (NASDAQ:MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced the appointment of Caren Deardorf as the company's first Chief Commercial Officer. "Caren has a highly sought-after balance of commercial success and hands-on experience, and we welcome her wide-ranging enterprise leadership expertise," said Jason Gardner, D.Phil., Chief Executive Officer and President, Magenta Therapeutics. "I look forward to working with her in establishing this new functionality as Magenta prepares to enter the next stage of pipeline and product candidate development." As Chief

      7/6/21 8:00:00 AM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLMD
    $MGTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Magenta Therapeutics Inc. (Amendment)

      SC 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

      2/14/24 4:58:16 PM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Magenta Therapeutics Inc. (Amendment)

      SC 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

      2/14/24 4:16:19 PM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Magenta Therapeutics Inc. (Amendment)

      SC 13G/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Subject)

      2/14/24 4:15:58 PM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TLMD
    $MGTA
    SEC Filings

    See more
    • SEC Form S-1/A filed by Magenta Therapeutics Inc. (Amendment)

      S-1/A - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

      2/7/24 4:52:11 PM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Magenta Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

      1/22/24 7:34:29 AM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Magenta Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Dianthus Therapeutics, Inc. /DE/ (0001690585) (Filer)

      1/8/24 8:02:01 AM ET
      $MGTA
      Biotechnology: Pharmaceutical Preparations
      Health Care